In a recent phase I trial of atezolizumab (anti-PD-L1) involving 45 patients with metastatic melanoma [27], the overall response rate was 30% among 43 efficacy evaluable patients, and the median response duration was 62 months. This evidence concerns the gene CD274 and metastatic melanoma.